Investigation of pregnancy associated plasma protein‐A and neopterin levels in Behçet's patients

Abstract

Behçet's disease (BD) is an autoimmune disease that affects many organs. We aimed to investigate the relationship between BD and these pregnancy‐associated plasma protein A (PAPP‐A), neopterin, and high sensitive C‐reactive protein (hsCRP) parameters. The study included 57 BD patients and 54 healthy controls. After evaluating the active and inactive disease status of the patients, analyzes were performed. When comparing the patient and control groups, neopterin (111.27 ± 37.49; 76.77 ± 38.27 [nmol/L]; P < .001) and hsCRP (11.81 ± 16.8; 3.62 ± 5.06 [mg/L]; P = .001) parameters were significantly higher in patients. Neopterin (117.68 ± 41.67; 94.85 ± 14.75 [nmol/L]; P = .038) and hsCRP (14.68 ± 18.7; 4.47 ± 7.27 [mg/L]; P = .002) found different in active and inactive patients. The sensitivities of neopterin and hsCRP were also found to be high in BD (respectively 93%, 67%). PAPP‐A was especially elevated in skin pathologies (P = .02) and neopterin in joint involvement (P = .03). We think that the use of neopterin and hsCRP can help in diagnosis and follow‐up of BD.

A systematic review and meta-analysis of neopterin in rheumatic diseases

“…Thirty studies (34 study groups) reported serum or plasma neopterin concentrations in a total of 2,618 RD patients (mean age 43 years, 32% males) and 5,318 healthy controls (mean age 42 years, 47% males) ( 55 , 59 , 61 , 64 – 67 , 69 – 87 , 89 , 90 ).…”

“…Twenty studies were conducted in Asia ( 55 , 59 , 65 , 66 , 69 , 70 , 72 – 74 , 77 , 78 , 80 – 82 , 84 – 89 ), six in Europe ( 61 , 62 , 64 , 67 , 79 , 90 ), three in Africa ( 71 , 75 , 83 ), and the remaining one in America ( 76 ). Ten study groups included patients with RA ( 55 , 76 , 78 – 81 , 83 , 86 , 89 , 90 ), nine with SLE ( 55 , 65 , 70 , 71 , 75 – 77 , 82 , 84 ), eight with BD ( 59 , 65 , 66 , 69 , 72 – 74 , 87 ), three with IIM ( 62 , 88 ), two with pSS ( 64 , 67 ), one with SSc ( 61 ), and one with AS ( 85 ). The analytical methods used for measuring neopterin included an enzyme-linked immunosorbent assay (ELISA) in 18 studies ( 61 , 64 – 67 , 69 – 71 , 74 – 76 , 78 , 79 , 81 , 85 , 86 ,...…”

“…Ten study groups included patients with RA ( 55 , 76 , 78 – 81 , 83 , 86 , 89 , 90 ), nine with SLE ( 55 , 65 , 70 , 71 , 75 – 77 , 82 , 84 ), eight with BD ( 59 , 65 , 66 , 69 , 72 – 74 , 87 ), three with IIM ( 62 , 88 ), two with pSS ( 64 , 67 ), one with SSc ( 61 ), and one with AS ( 85 ). The analytical methods used for measuring neopterin included an enzyme-linked immunosorbent assay (ELISA) in 18 studies ( 61 , 64 – 67 , 69 – 71 , 74 – 76 , 78 , 79 , 81 , 85 , 86 , 88 , 90 ), liquid chromatography with fluorimetric detection in 10 ( 55 , 72 , 73 , 77 , 80 , 82 – 84 , 87 , 89 ), and radioimmunoassay in two ( 59 , 62 ). Serum was analysed in 26 studies ( 55 , 59 , 61 , 62 , 64 – 67 , 69 – 74 , 76 – 78 , 81 …”

“…The analytical methods used for measuring neopterin included an enzyme-linked immunosorbent assay (ELISA) in 18 studies ( 61 , 64 – 67 , 69 – 71 , 74 – 76 , 78 , 79 , 81 , 85 , 86 , 88 , 90 ), liquid chromatography with fluorimetric detection in 10 ( 55 , 72 , 73 , 77 , 80 , 82 – 84 , 87 , 89 ), and radioimmunoassay in two ( 59 , 62 ). Serum was analysed in 26 studies ( 55 , 59 , 61 , 62 , 64 – 67 , 69 – 74 , 76 – 78 , 81 – 85 , 87 – 90 ), and plasma in the remaining four ( 75 , 79 , 80 , 86 ). RD duration, reported in 11 study groups, ranged between four and 11 years ( 61 , 67 , 71 , 73 – 75 , 78 , 80 , 81 , 83 , 90 ).…”

Assessment of serum neopterin and calprotectin as biomarkers for subclinical inflammation in patients with familial Mediterranean fever

“…Cell-mediated immunity is also activated in various neurological, cardiovascular, infectious, autoimmune diseases, and malignancies, proving this marker’s increased levels [ 30 ]. Previous studies found NPT increases in the body fluids of patients such as polycystic ovary syndrome, RA, SpA, diabetes mellitus, SLE, multiple sclerosis, celiac disease, and IBD [ 31 – 34 ]. Elevated urinary or serum NPT levels suggest a poor prognosis in cancer patients [ 35 ].…”